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Early Progressive Renal Decline
Precedes the Onset of
Microalbuminuria and Its
Progression to Macroalbuminuria
OBJECTIVE
Progressive decrease in the glomerular filtration rate (GFR), or renal decline, in
type 1 diabetes (T1D) is observed in patients with macroalbuminuria. However,
it is unknown whether this decline begins during microalbuminuria (MA) or
normoalbuminuria (NA).
RESEARCH DESIGN AND METHODS
The study group (second Joslin Kidney Study) comprises patients with T1D and NA
(n = 286) orMA (n = 248) whowere followed for 4–10 years (median 8 years). Serial
measurements (median 6, range 3–16) of serum creatinine and cystatin C were
used jointly to estimate GFR (eGFRcr-cys) and assess its trajectories during
follow-up.
RESULTS
Renal decline (progressive eGFRcr-cys loss of at least 3.3% per year) occurred in
10% of the NA and 35% of the MA (P , 0.001). In both groups, the strongest
determinants of renal decline were baseline serum concentrations of uric acid
(P , 0.001) and tumor necrosis factor receptor 1 or 2 (TNFR-1 or -2, P , 0.001).
Other significant risk factors included baseline HbA1c, age/diabetes duration, and
systolic blood pressure. Relative impacts of these determinants were similar in NA
and MA. Renal decline was not associated with sex or baseline serum concen-
tration of TNF-a, IL-6, IL-8, IP-10, MCP-1, VCAM, ICAM, Fas, or FasL.
CONCLUSIONS
Renal decline in T1D begins during NA and it is determined by multiple factors,
similar to MA. Thus, this early decline is the primary disease process leading to
impaired renal function in T1D. Changes in albumin excretion rate, such as the
onset of MA or its progression to macroalbuminuria, are either caused by or de-
velop in parallel to the early renal decline.
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It has generally been assumed that in
type 1 diabetes (T1D), increase in
urinary albumin excretion rate (AER)
precedes the development of impaired
renal function and end-stage renal
disease (ESRD). In that model, the onset
of microalbuminuria (MA) leads to
macroalbuminuria, and the latter is
followed by progressive glomerular
filtration rate (GFR) loss, or renal
decline, which eventually leads to ESRD
(1). A recently published large follow-up
observation of the Diabetes Control and
Complications Trial (DCCT)/
Epidemiology of Diabetes Interventions
and Complications (EDIC) cohort
showed that macroalbuminuria was a
strong predictor of the development of
chronic impaired renal function (GFR
,60 mL/min) (2).
This finding, although consistent with
the above model of diabetic
nephropathy, is open for different
interpretations. The authors assumed a
priori that abnormalities in AER would
precede significant GFR loss and did not
test the alternative possibility that so-
called early progressive renal decline
when GFR falls within the normal range,
i.e., from 130 to 60 mL/min, might
precede the development of
macroalbuminuria. It is also possible
that early progressive renal decline and
the development of AER abnormalities
are two clinical phenotypes that reflect
the disease process underlying diabetic
nephropathy that eventually results in
ESRD. These phenotypes may develop in
parallel and would be predictors of each
other.
Recently, better tools for tracking GFR
trajectories have been developed (3,4).
They allow the examination of the above
models and, particularly, the
establishment of which of the two
phenotypes appears first in the clinical
manifestation of diabetic nephropathy.
Using some of these tools, we already
revealed that progressive renal decline
commences earlier than previously
recognized and is already present in
patients with MA (5,6). In our earlier
follow-up studies of T1D (the first and
second Joslin Kidney Study on the
Natural History of Microalbuminuria),
progressive renal decline developed in
one-third of the patients with MA (5).
Furthermore, renal decline was strongly
associated with serum concentrations
of uric acid and concentrations of tumor
necrosis factor receptor 1 or 2 (TNFR-1
or -2) (6,7). Whether the effects of uric
acid and the TNFRs are independent is
unknown. Furthermore, due to limited
follow-up data on patients with
normoalbuminuria (NA), we were not
able to establish whether renal decline
can begin in patients with NA and, if so,
whether its determinants are similar as
in patients with MA.
To answer these questions, we
expanded our previous study in patients
with T1D and NA as well as withMAwho
had been followed with serial
measurements of serum creatinine and
cystatin C. We combined both markers
to derive the most precise indirect
measurement of the GFR (eGFRcr-cys)
and trace its changes/trajectories during
follow-up (4). Clinical characteristics
and serum concentrations of markers
previously reported in cross-sectional
analyses of this cohort (8) were
examined as determinants of
progressive renal decline.
RESEARCH DESIGN AND METHODS
The Committee on Human Studies of the
Joslin Diabetes Center approved the
protocol and informed consent
procedures for the second Joslin Kidney
Study on the Natural History of
Microalbuminuria, referred to here as
the 2nd JKS. A description of the Joslin
Clinic population and the design of the
study were reported with results of a
cross-sectional examination of the
cohort (8). Previous reports of the
shorter follow-up of this cohort included
only patients with high NA andMA (6,7).
The current study includes all patients
with baseline NA as well as MA and
extends follow-up to median 8 years
(25th and 75th percentiles accordingly
6–9 years).
Study Population
Participants in the 2nd JKS were
recruited from among patients
attending the Joslin Clinic, a major
center for treatment of patients with
diabetes. During the screening period,
1 January 2003 through 31 December
2006, patients scheduled for an
appointment at the Joslin Clinic were
evaluated for eligibility in the clinical
data system. Eligibility criteria included
residence in New England, T1D
diagnosed before age 40 years, current
age 18–64 years, and diabetes duration
3–39 years. The archived clinical
laboratory results during the 2-year pre-
enrollment interval were searched for
measurements of albumin-to-creatinine
ratio (ACR) in urine specimens.
In the Joslin Clinic, laboratory albumin
concentration in spot urine was
measured by immunonephelometry
on a BN Prospec System Nephelometer
(Dade Behring, Inc., Newark, DE) with N
Albumin kits, with intra-assay and
interassay coefficients of variation 4 and
6%, respectively. Creatinine
measurements in urine were assayed by
Jaffe’s modified picrate method on a
Ciba Corning Express Plus Chemistry
Analyzer (inter- and intra-assay
coefficients of variation 3 and 5%,
respectively). Individual values for ACR
(measured in milligrams per gram) were
converted to AERs (in micrograms per
minute) by the previously published
formula log(AER) = 0.44 + (0.85)log(ACR)
– (0.13)sex, where sex is assigned a
value of 1 for female patients and 0 for
male patients (9).
Patients were not eligible for enrollment
if they had macroalbuminuria (median
pre-enrollment AER $300 mg/min),
were on dialysis, had received a renal
transplant, or had a history of HIV or
hepatitis C infection. Among the 4,000
residents of New England with T1D who
attended the Joslin Clinic during the
screening period, we identified 2,667
eligible patients: 2,007 with NA (pre-
enrollment median AER ,30 mg/min)
and 660 with MA (pre-enrollment
median AER 30–299 mg/min). Ninety-
five percent were white.
Enrollment and Examination
The study aimed to enroll eligible
patients with MA and a similar number
of eligible patients from the much larger
pool of patients with NA. Furthermore,
since the number of eligible NA patients
with a pre-enrollment AER,15 mg/min
was much larger than the number with
an AER 15–29 mg/min, we sought to
enroll only one patient with an AER,15
mg/min for each patient enrolled with
an AER 15–29 mg/min. Study recruiters
approached patients who had been
identified as eligible when they arrived
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for a scheduled appointment at the
clinic. After informing patients about
the study and obtaining their written
consent to participate, the recruiter
1) administered a structured interview
that solicited the history of diabetes and
its treatment, other health problems,
and medications; 2) measured blood
pressure; and 3) obtained specimens of
blood and urine for laboratory
determinations. Measurements of AER
at enrollment examination were
combinedwith AERmeasurements from
the preceding 2-year pre-enrollment
interval, and new medians were
determined to represent the baseline
AER values. For all other characteristics,
baseline values are those obtained at
enrollment examination. As of the end
of 2006, we had examined 304 patients
with MA and 363 patients with NA.
Patients recruited into the 2nd JKS
during a second phase (2007–2010) are
not included in this report.
Follow-up Examinations
Enrolled participants were followed
until 2013, with a goal to obtain blood
and urine specimens at least every 2
years. Collection of research specimens
occurred during patients’ routine clinic
visits. Although most patients had two
or more visits per year, the research
specimens were collected less
frequently, on average 1.5 years apart.
Patients with less frequent visits to the
clinic or those who stopped coming to
the clinic were examined at their homes.
Specimens obtained at baseline and
during follow-up were stored at 2808C
for later analysis.
Determinations of AER performed
during routine clinic visits and for
research purposes were combined and
used to evaluate changes in AER over
time (all measurements were
performed in the Joslin Clinic laboratory
as described above). We considered
three 2-year intervals: the baseline
interval and the first and second 2-year
intervals after enrollment. In patients
with NA during the baseline interval, a
median AER .30 mg/min in either 2-
year follow-up interval constituted the
onset of MA. In patients with MA during
the baseline interval, a halving of
baseline AER constituted regression of
MA and the development of
macroalbuminuria (.300 mg/min) in
either follow-up interval constituted
progression.
Laboratory Measurements
Serum Markers
Protocols for measuring concentration
of TNF-a (free) and its receptors (TNFR-1
and -2) and other markers such as IL-6,
IL-8, IP-10, MCP-1, VCAM, ICAM, Fas,
and FasL as well as uric acid were
described previously (6,8).
Estimation of GFRcr-cys
From 2009 to 2013, creatinine and
cystatin C were assayed in stored
baseline and follow-up serum samples
in the Advanced Research and
Diagnostic Laboratory at the University
of Minnesota. Protocols used for
creatininemeasurements yielded values
traceable to isotope dilution mass
spectrometry reference measurement
procedures, and, for the cystatin C,
values were adjusted to be traceable to
ERM-DA471/IFCC international
reference material as described
previously (10). The eGFRcr-cys was
estimated with the recently published
combined creatinine-cystatin C Chronic
Kidney Disease Epidemiology
Collaboration (CKD-EPI) formula (4).
Definition of Progressive Renal
Decline
Longitudinal measures of log-
transformed eGFRcr-cys values were
analyzed with linear mixed-effects
regression (PROC MIXED, SAS V 9.3; SAS
Institute, Cary, NC). This approach takes
into account the correlation between
follow-up observations from a patient
taken at varying intervals. It yields
individual-specific slope coefficients
that are re-expressed as percent change
per year in eGFRcr-cys (6). Progressive
renal decline is defined as a negative
change equal to or steeper than 23.3%
per year, and the patient is referred to as a
“decliner.” Less steep slopes are defined
as stable, and the patients are referred to
as “nondecliners.” This criterion, an eGFR
loss of 3.3% per year or more, has been
used in previous reports (5,6) and
corresponds to the 2.5th percentile of the
distribution of annual renal function loss
in a general population (11).
Statistical Analysis
All statistical analyses were performed
in SAS V 9.3. Comparisons between
those with renal decline and those with
stable eGFRcr-cys were made with
Wilcoxon rank sum tests for continuous
variables and x2 test for categorical
variables. The risk of renal decline
(eGFRcr-cys loss $3.3% per year)
according to clinical characteristics or
baseline serum marker concentrations
categorized into quartiles of their
distributions or according to other
ordinal variables was tested using the
Cochran-Armitage trend test. A multiple
logistic regression model was used to
jointly test the predictors of eGFR
decline identified in univariate analysis.
P values ,0.05 were considered
significant. The analyses were
performed in SAS V 9.3 software.
RESULTS
Progressive Renal Decline in the Study
Groups
There were 304 patients with MA and
364 patients with NA enrolled in the 2nd
JKS. This study included those with
normal renal function at baseline
(eGFRcr-cys .60 mL/min) who were
followed for 4–10 years: 248 (82%)
patients with MA and 286 (79%) with
NA. Characteristics of the study groups
are summarized in Table 1. In
comparison with the NA group, the MA
group included more males; had a
longer duration of diabetes, higher
HbA1c, and higher blood pressure; and
was more frequently treated with
renoprotective drugs. Whereas the
distribution of AER in the NA group was
uniform across the normal range (,30
mg/min), the bulk of the distribution in
the MA group was in the low abnormal
range (25th, 50th, and 75th percentiles
were 44, 65, and 116 mg/min,
respectively). The distributions of baseline
concentrations of serum creatinine and
cystatin C and the estimates of eGFRcr-cys
were similar in NA and MA.
Duration of follow-up and the available
number of measurements of serum
creatinine and cystatin C were similar in
the two study groups. The annual rate of
eGFRcr-cys change was estimated from
these serial measurements. The median
rate of loss in patientswithMAwasmore
rapid than in patients with NA. Renal
decline (rate of eGFRcr-cys loss $3.3%
per year) was present in 10% of the NA
group and 35% of the MA group.
Impaired renal function (CKD-EPI$3)
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developed in 6%of theNA group and 22%
of the MA group, and ESRD developed in
one of the former and four of the latter.
The trajectories of renal function
changes in the 28 decliners with NA
have particular significance because
they have not been documented before
(Fig. 1). To improve visibility of
individual slopes, the 28 patients are
stratified at the median baseline
eGFRcr-cys ($105mL/min in Fig. 1A and
,105 mL/min in Fig. 1B). Two features
deserve emphasis. First, the majority of
trajectories of eGFRcr-cys loss were
approximately linear. Two deviated
visibly by accelerating the rate of decline
(trajectories in red). These accelerations
were accompanied by the onset of MA
and macroalbuminuria. One of these
patients has reached ESRD and the other
soon will. Second, the slopes of eGFRcr-
cys loss varied tremendously, ranging
from a loss of 3.3 to 21% per year. The
fastest decliners, including the two
already mentioned, will reach ESRD
within 5–15 years, and the slowest
might take 25–30 years. The pattern of
eGFRcr-cys trajectories in 86 decliners
withMAwas similar; i.e., the majority of
trajectories were linear and four
patients rapidly progressed to ESRD
within the duration of follow-up (data
not shown due to large number of
decliners).
Univariate Analysis of Determinants
of Progressive Renal Decline
To find determinants of renal decline,
we compared nondecliners with
decliners with regard to baseline clinical
covariates and serum concentrations of
12 markers separately in patients with
NA and MA (Table 2). The values of
eGFRcr-cys at last follow-upwere similar
to baseline for nondecliners in both
groups. For decliners, however, the last
values were lower (by definition) than
baseline, down to 61 from 104 mL/min
in NA and to 59 from 99 mL/min in MA.
The median rate of eGFRcr-cys loss per
year in decliners was 5.0% per year in
both groups. Renal function at baseline
in patients with NA was normal in
nondecliners but was already lower in
decliners, most likely because the onset
of renal decline preceded the
enrollment in the study. Similarly in
patients with MA, renal function at
baseline was normal in nondecliners
(despite the presence of MA) but was
already lower in decliners for the same
reason.
During the baseline interval, AER was
identical in decliners and nondecliners
in the NA group, but MA developed in
three times as many decliners (54%) as
nondecliners (17%) during the 4 years of
follow-up. In patients with MA already
present during the baseline period,
progression to macroalbuminuria was
much more common in decliners (27%)
than nondecliners (4%) during the 4
years of follow-up. By contrast, AER
Table 1—Characteristics of the study groups
NA MA
Baseline characteristics n = 286 n = 248
Male (%) 43% 62%
Duration of diabetes (years) 20 (14–29) 24 (15–30)
Age (years) 41 (30–48) 42 (34–49)
HbA1c (%) 8.0 (7.4–8.8) 8.3 (7.5–9.3)
HbA1c (mmol/mol) 64 (57–73) 67 (58–78)
Systolic blood pressure (mmHg) 118 (110–127) 122 (114–130)
Diastolic blood pressure (mmHg) 70 (68–76) 72 (70–80)
ACE and ARB Rx 33% 74%
AER (mg/min) 16 (12–22) 65 (44–116)
Serum cystatin C (mg/L) 0.65 (0.58–0.72) 0.66 (0.60–0.78)
Serum creatinine (mg/dL) 0.76 (0.65–0.86) 0.79 (0.69–0.90)
eGFRcr-cys (mL/min) 113 (102–123) 112 (96–122)
Follow-up characteristics
Duration of follow-up (years) 8.0 (6.0–8.7) 7.9 (5.5–9.2)
Number of serum samples 5 (4–7) 7 (5–9)
eGFRcr-cys loss (% per year) 21.5 (22.4 to 20.8) 22.2 (24.1 to 21.2)
Renal decline (eGFRcr-cys loss
‡3.3%/year) 10% 35%
8-year cumulative risk of CKD-EPI $3 6% 22%
ESRD (n) 1 4
Data are percents or medians (25th–75th percentiles). ARB, angiotensin receptor blocker.
Boldface indicates main outcome measurement.
Figure 1—eGFRcr-cys trajectories in T1D patients with NA and progressive renal decline (loss
$3.3% per year) during 4–10 years of follow-up. The trajectories are plotted in patients with
baseline eGFRcr-cyst$105 mL/min (A) and in patients with baseline eGFRcr-cys,105 mL/min
(B). Lines in red indicate presence of macroalbuminuria. E, ESRD.
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regression was twice as common in
nondecliners (43%) as decliners (23%).
Thus, AER was more likely to progress in
patients with renal decline and more
likely to be transient in nondecliners.
With regard to other baseline
characteristics, decliners and
nondecliners did not differ in either
group with regard to sex, insulin dose,
BMI, serum cholesterol (total or HDL), as
well as cigarette smoking (data not
shown). Significant differences between
decliners and nondecliners are indicated
in the bottom part of Table 2. In both
study groups, age at entry into the study
was older and duration of diabetes was
longer for decliners than nondecliners.
In addition, the decliners had poorer
glycemic control and higher systolic
blood pressure and were treated more
frequently with renoprotective drugs
than nondecliners. In both study groups,
decliners had significantly higher serum
concentrations of uric acid, TNFR-1, and
TNFR-2 than nondecliners. Serum
markers such as free TNF-a, IL-6, IL-8, IP-
10, MCP-1, ICAM, VCAM, Fas, and FasL
were not different between decliners
and nondecliners (data not shown).
To visualize these associations, in Table
2 we graphed the risk of renal decline
separately by study group according to
categories of baseline characteristics
that were associated with renal decline
in the case-control analysis (Fig. 2). The
risk of renal decline according to
quartiles of baseline AER (Fig. 2A, top)
was flat (;10%) across quartiles in the
NA group. In MA, the risk of renal
function decline was significantly higher
than in NA and increased from 23% in
the lowest quartile to 55% in the
highest. For HbA1c, the increase in risk
was moderate in the NA group but
strong in theMA group (Fig. 2A). The risk
of decline increased with age in both
groups (Fig. 2A) and increased similarly
with duration of T1D because of its
correlation with age (data not shown).
Risk of decline also increased with
systolic blood pressure in both groups
(Fig. 2A) and increased as the number of
prescribed renoprotecting treatments
increased (Fig. 2B). Plots of the risk of
renal decline according to three serum
markers are shown in Fig. 2B. In both
study groups, elevated serum uric acid
increased the risk of renal decline, and
the effect of an increasing serum TNFR-1
or TNFR-2 was even more striking. The
effects of both TNFRs were very similar
and the information in them redundant.
Multivariate Analysis of Determinants
of Progressive Renal Decline
Determinants of renal decline that were
significant in Table 2 and Fig. 2 were
examined with multiple logistic
regression analyses. In separate
analyses of the NA and MA groups, the
coefficients for these determinants
were similar so we combined the groups
and included an indicator variable for
MA as one of the determinants (Table
3). The dose-response relationship
appeared stronger with age (Fig. 2A)
than with duration, so only age was
included in the model. Similarly, systolic
blood pressure (Fig. 2A) and number of
prescribed renoprotective drugs (Fig.
2B) were correlated. We only included
blood pressure in the model because
the intensity of treatment was most
likely secondary to the blood pressure,
Table 2—Characteristics of nondecliners and decliners according to study group
NA MA
GFR change during follow-up GFR change during follow-up
Characteristics
Nondecliner
(n = 249)
Decliner
(n = 28) P
Nondecliner
(n = 162)
Decliner
(n = 86) P
Renal function
eGFRcr-cys baseline 113 (103–124) 104 (91–117) ,0.005 116 (105–124) 99 (80–111) ,0.001
eGFRcr-cys last 103 (93–115) 61 (54–76) 103 (89–116) 59 (48–76) N/A
eGFRcr-cys slope (% per year) 21.3 (22.1 to 20.7) 25.0 (27.3 to 23.8) 21.5 (22.1 to 20.7) 25.1 (27.4 to 24.0) N/A
AER abnormality
AER baseline (mg/min) 16 (12–22) 16 (12–22) NS 57 (42–92) 94 (51–166) ,0.001
Onset of MA 17% 54% ,0.001 – –
Progression to
macroalbuminuria d d 4% 27% ,0.001
Persistent MA d d 54% 50%
Regression of MA d d 43% 23%
Baseline clinical characteristics
and serum markers*
Duration of T1D (years) 19 (13–28) 28 (22–32) ,0.005 23 (15–30) 27 (16–33) NS
Age (years) at examination 40 (28–47) 47 (44–58) ,0.001 39 (31–47) 45 (39–51) ,0.001
HbA1c (%) 8.0 (7.4–8.8) 8.4 (7.5–9.3) NS 8.1 (7.4–9.0) 8.7 (7.8–9.9) ,0.005
HbA1c (mmol/mol) 64 (57–73) 68 (58–78) NS 65 (57–75) 72 (62–85) ,0.005
Systolic blood pressure 118 (110–126) 123 (112–135) ,0.05 121 (112–130) 124 (118–133) ,0.005
Renoprotective drugs (%) 28% 69% ,0.001 69% 81% ,0.05
Serum uric acid (mg/dL) 4.1 (3.6–4.9) 4.8 (4.0–5.4) ,0.05 4.8 (4.2–5.7) 5.4 (4.2–6.4) ,0.05
Serum TNFR-1 (pg/mL) 1,256 (1,087–1,490) 1,509 (1,281–1,870) ,0.001 1,442 (1,229–1,700) 1,788 (1,454–2,220) ,0.001
Serum TNFR-2 (pg/mL) 1,986 (1,686–2,411) 2,601 (2,212–3,380) ,0.001 2,205 (1,892–2,652) 2,707 (2,180–3,385) ,0.001
Data are percents or median (25th–75th percentiles). *Concentrations of serum markers TNFs, IL-8, IP-10, MCP-1, ICAM, VCAM, Fas, and FasL in
decliners and nondecliners did not differ (data not shown).
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not the reverse. In a cross-tabulation of
patients according to both serum uric
acid and TNFR-1, the risk of renal decline
increased with each one alone, but their
effects were not additive. This is
reflected in the significant odds ratio
(OR) but smaller than 1.00 for their
interaction term in the multiple logistic
model (Table 3). An increase in one
diminishes the effect of the increase in
the other. For example, at the 25th
percentile of TNFR-1 (1,170 pg/mL), the
OR for the 75th vs. 25th percentiles of
uric acid is 3.72, whereas at the 75th
percentile of TNFR-1 (1690 pg/mL), it is
1.58. The relationship is symmetric. At
the 25th percentile of uric acid (3.8mg/dL),
the OR for the 75th vs. 25th percentiles
of TNFR-1 is 4.68, whereas at the
75th percentile of uric acid (6.4 mg/dL),
it is 1.99.
CONCLUSIONS
In this large follow-up study, we showed
that progressive renal decline in T1D
began during NA and, similar to MA, it
was determined by multiple factors. We
conclude that this early progressive
renal decline can be considered the
primary clinical manifestation of disease
process leading to impaired renal
function and eventually to ESRD in T1D.
Changes in AER observed during follow-
up, such as the onset of MA or its
progression to macroalbuminuria, were
either caused by or developed in parallel
to the early renal decline in T1D.
In our study of T1D patients with NA,
progressive renal decline developed in
10% (decliners) within 4–10 years of
follow-up, whereas only 2.5% was
expected if these patients had been
nondiabetics. The risk of renal decline
did not vary within the normal range of
AER in NA but increased with increasing
AER in the MA range. The rate of
eGFRcr-cys loss was continuous
(progressive decline) in the majority of
decliners and could be represented as a
linear slope. These slopes varied widely
in their steepness. For example, in the
study, eGFRcr-cys loss was so rapid in
five patients (one with NA and four with
MA) that they progressed from normal
renal function to ESRD within the 5–10
years of observation, whereas the
eGFRcr-cys loss in other decliners was
slow so that progression to ESRD might
take up to 30 years. These findings are
Figure 2—Risk of progressive renal decline according to categories of baseline clinical characteristics (A) and serum markers (B) and according to
study groups. aCut points for 25th, 50th, and 75th percentiles were 1,173, 1,394, and 1,685 pg/mL; bcut points for 25th, 50th, and 75th percentiles
were 1,810, 2,186, and 2,690 pg/mL.
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similar to the renal decline patterns we
observed in T1D patients with
macroalbuminuria (12).
Progressive renal decline was present
in a significant proportion of T1D
patients when their urinary albumin
excretion was normal, and it increased
the risk of onset of MA several fold
during follow-up in comparison with
nondecliners (51 vs. 17%). This finding
provides a very strong evidence that
early progressive renal decline is the
primary event in the development of
diabetic nephropathy. Furthermore,
once early progressive renal decline and
MA were both present, the risk of
progression to macroalbuminuria
during follow-up was several fold higher
in comparison with nondecliners with
MA (28 vs. 4%). Conversely, the
frequency of regression of MA in
nondecliners was twice that in decliners.
Thus, the abnormal AER that occurred in
the presence of early progressive renal
decline was more likely to be
progressive, whereas the abnormal
excretion that occurred in nondecliners
was more likely to be transient.
These findings are not consistent with
the generally assumedmodel of diabetic
nephropathy in which renal decline is a
consequence of or follows
macroalbuminuria (1). Instead, our
findings indicate that either both are
loosely correlated phenotypes of a
disease process that underlies diabetic
nephropathy and leads to ESRD or that
early progressive renal decline is one of
the causes of albuminuria. The former
interpretation of our findings explains
reports that showed that albuminuria
and renal decline are uncoupled
phenotypes in T1D (2,13,14) and T2D
(15). The latter should be considered
as a new hypothesis and should be
studied further.
Recognition that multiple clinical factors
contribute in a similar way to renal
decline in NA and MA strengthens our
hypothesis that progressive renal decline
is the primary clinical abnormality of
diabetic nephropathy. Following, we
discuss what is known of these factors.
As mentioned earlier, the effect of renal
decline on the risk of the onset of MA
and its progression to macroalbuminuria
may account in large degree for a higher
occurrence of renal decline in our
collection of patients ascertained for the
presence of MA. In other words, early
renal decline leads to MA, so patients
with MA should be enriched with those
at risk for renal decline. The effect of
HbA1c on renal decline was recently
recognized (16). In our study, the effect
of HbA1c on risk of early renal declinewas
strong. However, the mechanisms
through which hyperglycemia
contributes to early progressive renal
decline independently from AER
abnormalities are unknown. The effect
of increasing age on renal decline is
recognized in nondiabetic individuals
.40 years of age. The GFR loss of.3.3%
per year (about 4mL/min/year) occurs in
,3% of the healthy population (11). It is
unknown why such GFR loss occurred
almost 5–15 times more frequently in
T1D patients 40 years of age or more. In
part, this effect was due to a long
duration of diabetes. Since these two
covariates were closely correlated, it was
impossible to separate their effects in
this study. The risk of early progressive
renal decline increased with increasing
systolic blood pressure, a well-
documented risk factor for progression
to ESRD (17). Antihypertensive and
renoprotective drugs were prescribed in
patients with elevated blood pressure
and MA. In univariate analysis, both
elevated systolic blood pressure and
treatment with these drugs increased
the risk of early progressive renal
decline. However, in multivariate
analysis, the effect of the latter declined
significantly, indicating that
antihypertensive and renoprotective
treatment had an inconsequential effect
on the risk of early progressive renal
decline. Similar findings were recently
reported in the Renin-Angiotensin
System Study (RASS) clinical trial (18).
Of the 12 serum markers previously
examined in cross-sectional analyses of
this cohort (6–8), only the
concentrations of uric acid, TNFR-1, and
TNFR-2 significantly contributed to renal
decline. The effects of these markers on
the risk of renal decline were equally
strong in patients with NA or MA. The
congruence of these determinants in
MA and NA is further evidence for our
hypothesis that early progressive renal
function is the primary disease process
underlying the development of renal
decline in T1D and leads to ESRD.
The mechanisms underlying the
association between high normal values
of serum uric acid and increased risk of
renal decline are unclear at this time.
Serum uric acid has proinflammatory
properties and may act as either a pro-
oxidant or antioxidant molecule
depending on the circumstances (19). In
vitro, exposure to uric acid leads to
upregulation of cyclooxygenase-2,
specific mitogen-activated protein
kinases, various inflammatory
mediators, and the renin-angiotensin
system, as well as to inhibition of
endothelial nitric oxide production (20–
22), which may all contribute to the
development of kidney damage. In vivo,
rats rendered hyperuricemic by means
of a uricase inhibitor develop an afferent
arteriolopathy that decreases luminal
diameter and produces renal ischemia,
leading to glomerulosclerosis and
tubulointerstitial fibrosis (23). Similar
histological changes occur in humans
with gouty nephropathy (24). Lowering
serum uric acid concentration with
allopurinol attenuates these histological
and functional changes, although this
effect may be due in part to reduced
Table 3—Multiple logistic analysis of determinants of renal decline in both study
groups combined
Baseline determinants OR 95% CI x2 P
Age (per 10 years) 1.53 1.18–1.97 10.7 0.0011
HbA1c (per 1%) 1.60 1.31–1.95 20.9 ,0.0001
Systolic BP (per 10 mmHg) 1.34 1.09–1.63 8.4 0.0038
MA vs. NA 2.28 1.28–4.08 7.7 0.0054
Uric acid (per 0.5 mg/dL) 1.86 1.33–2.62 12.8 0.0003
TNFR-1 (per 200 pg/mL) 2.93 1.90–4.52 23.6 ,0.0001
Interaction (TNFR-1 and uric acid) 0.94 0.91–0.97 12.2 0.0005
BP, blood pressure.
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oxidative stress resulting from xanthine-
oxidase inhibition (19). It is intriguing to
postulate that lowering serum uric acid
in patients at risk for renal decline may
be an effective intervention to reduce
the risk of renal decline in T1D (25).
Preparations for such clinical trials are
under way (26).
Our previous studies described the
strong effect of serum concentrations of
TNFR-1 or TNFR-2 on the risk of
advanced stages of renal decline such as
CKD-EPI $33 or ESRD (7,27). This study
extends the demonstration of their
effects to the onset of the process of
renal decline itself.We do not knowhow
elevated concentrations of TNFRs
initiate renal decline and lead to renal
failure. However, some hypotheses
were excluded by this study. For
example we showed that serum TNF-a is
not involved directly or indirectly,
through regulation of serum TNFRs, in
the development of renal decline.
Furthermore, we excluded the role of
several circulating adhesion molecules
and chemokines (VCAM, ICAM, IL-6,
IL-8, IP-10, andMCP-1) in the etiology of
renal decline as potential downstream
effectors of TNFRs (8).
An intriguing finding of the current
study is the negative interaction
between serum uric acid and TNFR-1 on
the risk of renal decline in both NA and
MA, meaning that the risk of renal
decline for patients with elevated serum
uric acid and serum TNFR-1 is less than
the sum of the individual risks
associated with the two predictors. This
suggests that the predisposing effects of
serum uric acid and TNFR-1 converge on
some common pathway that cannot be
further activated by one factor if it has
already been turned on by the other.
The nature of this putative pathway is
unknown at this time.
Finally, the limitations of our study must
be considered. First, our major
weakness is the lack of direct
measurements of GFR. The eGFRcr-cys
equation has not been validated in T1D,
and this type of eGFR assessment may
significantly underestimate
“hyperfiltration” in T1D, therefore
reducing the steepness of eGFR slopes
and underestimating the true frequency
of early progressive renal decline.
Second, our study is descriptive and
hypothesis generating, and it cannot
directly shed any light on the
mechanisms of early progressive renal
decline in T1D. However, it provides
novel data that question many
assumptions about the natural history
of diabetic nephropathy in T1D. Third,
this study was conducted in T1D and the
generalizability of the findings to T2D is
uncertain.
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